DRKS00029223已完成不适用
Guillain-Barré syndrome: patient characteristics and early symptoms as potential predictors of later outcome and degree of independence - a retrospective analysis
ehrstuhl für Neurologie an der Universität Witten/Herdecke0 个研究点目标入组 127 人开始时间: 2022年6月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 127
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one(—)
- 性别
- All
入选标准
- •Diagnosis of Guillain-Barré syndrome confirmed according to the diagnostic guidelines of the German Society of Neurology and GBS is the main diagnosis for the rehabilitation measure.
- •- acute GBS with the ICD-10 code G61.0 of the variants Acute Inflammatory Demyelising Polyneuropathy, Acute Motor Axonal Polyneuropathy, Acute Motor Sensory Axonal Polyneuropathy or the Miller-Fisher Syndrome
- •- Patient must be at least 18 years old
- •- Inpatient stay at Rehanova, which ended by 30.06.2021 and lasted at least 14 days
- •- referral was made by the hospital where the diagnosis of GBS was made and the rehabilitation immediately followed the hospital stay
- •- in the case of interruption and later resumption of the rehabilitative measure (e.g. due to necessary transfer to a hospital), the period of interruption was shorter than three months
- •Translated with www.DeepL.com/Translator (free version)
排除标准
- •- Diagnosis of GBS is listed as an unconfirmed suspected diagnosis.
- •- Presence of chronic GBS or an acute variant other than those mentioned above (e.g. Elsberg syndrome).
- •- the patient was transferred to Rehanova from another rehabilitation facility
- •- it is not the first rehabilitation for the disease, but a renewed measure due to residual symptoms
研究者
相似试验
已完成
不适用
Prognosis of Guillain-Barré Syndrome in Children.acute inflammatory demyelinating polyneuropathy (AIDP)no lay-term10034606NL-OMON33503Erasmus MC, Universitair Medisch Centrum Rotterdam50
已完成
2 期
A Study of Imlifidase in Patients With Guillain-Barré SyndromeGuillain-Barré Syndrome (GBS)NCT03943589Hansa Biopharma AB30
招募中
不适用
Innate immunity in the Guillain-Barré syndromeNL-OMON45725Erasmus MC, Universitair Medisch Centrum Rotterdam124
已完成
3 期
Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré SyndromeGuillain-Barré SyndromeNCT02221271Nihon Pharmaceutical Co., Ltd22
尚未招募
不适用
Prognostic Indicators of Gullian-Barre SyndromeGuillain-Barre SyndromeNCT06300359Assiut University60
